
Bupi0.5%
Popular Pharmaceuticals Ltd.
Bupivacaine Hydrochloride is a long-acting amide-type local anesthetic indicated for the production of local or regional anesthesia and analgesia in adults and, in specific clinical circumstances and more.
Bupivacaine Hydrochloride is a long-acting amide-type local anesthetic indicated for the production of local or regional anesthesia and analgesia in adults and, in specific clinical circumstances, older pediatric patients. Established, FDA-approved uses include:
Bupivacaine Hydrochloride is not recommended for intravenous regional anesthesia (Bier block) or obstetric paracervical block, and the 0.75% concentration must never be used for obstetric epidural anesthesia (see Contraindications). It is also used off-label, based on clinical experience, for continuous wound infiltration and intra-articular administration for postoperative pain, although intra-articular infusion is not an approved use and carries a specific risk (see Precautions and Warnings).
Dosage of Bupivacaine Hydrochloride depends on the procedure, the site and route of administration, the vascularity of the tissue, individual patient tolerance, and the concentration/volume used. The lowest concentration and dose producing the desired effect should always be used, and the maximum recommended single dose should not be exceeded.
| Indication | Typical Concentration | Approximate Adult Dose |
|---|---|---|
| Local infiltration | 0.25% | Up to 175 mg (up to 70 mL of 0.25%) per single dose |
| Peripheral nerve block | 0.25%–0.5% | Individualized; typically 12.5–150 mg depending on nerve(s) blocked |
| Lumbar epidural (surgical) | 0.5%–0.75% | 25–150 mg per injection, incremental dosing |
| Lumbar epidural (obstetric labor) | 0.25%–0.5% only (0.75% contraindicated) | Individualized; incremental low-dose administration |
| Caudal block | 0.25%–0.5% | 37.5–150 mg |
| Retrobulbar block | 0.75% | 15–30 mg (2–4 mL) |
The maximum total dose in adults should generally not exceed 400 mg in a 24-hour period, and repeat doses should not be given more frequently than every 3 hours, adjusted for patient factors and clinical response. Bupivacaine Hydrochloride must be administered only by, or under the supervision of, clinicians experienced in regional anesthesia, with resuscitation equipment and drugs (including lipid emulsion for local anesthetic systemic toxicity) immediately available. Careful aspiration before and during injection is essential to avoid inadvertent intravascular injection, and incremental (fractionated) dosing is recommended for epidural and other major nerve blocks.
Most adverse effects of Bupivacaine Hydrochloride are dose-related and result from high plasma concentrations due to rapid absorption, inadvertent intravascular injection, or metabolic slowing.
Bupivacaine Hydrochloride is contraindicated in the following situations:
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.